VWF and ADAMTS13 behavior in estradiol-treated HUVEC

Area of Science:

• Endocrinology and Molecular Biology
• Vascular Biology and Thrombosis

Background:

• 17β-estradiol (E2) is a key hormone influencing cardiovascular health.
• Von Willebrand factor (VWF) and ADAMTS13 are critical proteins in hemostasis and thrombosis.
• Endothelial cells play a central role in regulating VWF and ADAMTS13.

Purpose of the Study:

• To investigate the role of 17β-estradiol (E2) in the regulation of VWF and ADAMTS13 synthesis, storage, and secretion.
• To explore the impact of E2 on VWF and ADAMTS13 gene expression and protein production in human umbilical vein endothelial cells (HUVEC).

Main Methods:

• HUVEC were treated with E2 (1 nm) or vehicle.
• VWF and ADAMTS13 levels were measured in cell lysates and supernatants using VWF:Ag, multimeric analysis, and SDS-PAGE.
• Gene expression of VWF and ADAMTS13 was quantified by real-time PCR.
• ADAMTS13 function was assessed via knockdown using shRNA.

Main Results:

• E2 did not alter VWF release or intracellular levels.
• E2 significantly increased intracellular ADAMTS13 production and mRNA expression for both VWF and ADAMTS13.
• Knockdown of ADAMTS13 upregulated VWF release and intracellular levels in E2-treated HUVEC.

Conclusions:

• E2 regulates VWF and ADAMTS13 gene expression and production in human endothelial cells.
• Intracellular regulation of VWF by ADAMTS13 may mediate the cardiovascular protective effects of E2.
• These findings elucidate a novel mechanism for E2's role in vascular health.